---
schema_version: "secwatch.filing_event.v1"
accession: "0001714899-25-000067"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:15:15.037705+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Denali reports FY2024 net loss $422.8M; BLA for MPS II drug planned early 2025

## Summary
- Net loss $114.8M Q4 and $422.8M FY2024, vs $119.5M and $145.2M in prior year.
- No collaboration revenue in 2024; FY2023 had $330.5M from Biogen, Sanofi, Takeda.
- New ATM equity facility up to $400M; prior ATM terminated; Goldman & Leerink agents.
- DNL343 (ALS) missed primary endpoint in HEALEY trial; further analyses expected H2 2025.
- 2025 cash opex guided +10-15% vs 2024; cash balance $1.19 billion as of Dec 31.

## SEC filing metadata
- accession: 0001714899-25-000067
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 1.02, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000171489925000067/0001714899-25-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000171489925000067/dnli-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001714899-25-000067
- JSON: https://secwatch.observer/filing/0001714899-25-000067.json
- Plain text: https://secwatch.observer/filing/0001714899-25-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.